Eamonn Hobbs Joins the Board of Directors at Cappella

GALWAY, Ireland, February 17, 2010 - Cappella (www.cappella-med.com/), Inc. (Cappella), a medical
device company developing dynamic solutions for the treatment of coronary
bifurcation disease, announced the addition of Mr. Eamonn Hobbs to the Board
of Directors (
www.cappella-med.eu/index.php?option=com_content&view=article&id=181:board-of-directors&catid=4)
. According to Mr. Wolfgang Oster, MD, PhD, Chairman of the Board and
Managing Partner at PolyTechnos Venture-Partners GmbH, "Eamonn's wealth of
expertise and solid track record of success in our medical device field
makes him a formidable source of wisdom and judgement for the road ahead of
Cappella. The company's commercial programs and global market expansion will
greatly benefit from Mr Hobbs' insights."

Mr. Eamonn Hobbs, President, CEO, & Director of Delcath Systems, Inc. is
an entrepreneurial senior executive with over 25 years of medical device
experience and demonstrated success in profitable business creation, general
management, sales and marketing and product development. When asked to
comment on his recent appointment, Mr. Hobbs stated, "I am delighted to join
Cappella's Board of Directors and support the cause of this company which is
all about addressing a substantial unmet medical need. Whereas long
under-diagnosed and under-served, bifurcational lesions have now attracted
the much deserved attention of the medical community and I am convinced that
Cappella has put the best team on the field to tackle the challenge. I am
thrilled to work with Dr. Art Rosenthal and our Board of Directors to deliver
this technology to patients in need."

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions
for the treatment of complex Coronary Artery Disease (CAD) and specifically
bifurcation vascular disease. Cappella's initial product, the Sideguard(R)
(www.cappella-med.eu/index.php?option=com_content&view=article&id=1&Itemid=2)
Coronary Sidebranch Stent & Delivery System offers interventional
cardiologists a straightforward, effective solution that focuses on treating
the sidebranch of diseased coronary arteries first, rather than the main
vessel. More importantly, it allows the preferred stent of choice for the
main vessel. An optimal stent design specific to the anatomy of the
sidebranch, combined with the qualities of Nitinol now provide a dynamic
solution for treating sidebranch disease. Cappella Medical Devices Ltd.,
Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For
more information, see: www.cappella-med.com.

(Due to the length of some of the URLs in this release, it may be
necessary to copy and paste the hyperlinks into your Internet browser's URL
address field. Remove the space if one exists.)

Links: Cappella : www.cappella-med.com/

Contact: Claire Marie Gigon, Cappella Medical Devices Limited, Tel: +41-(0)79-374-57-65, Email: cmgigon at cappella.ie